TREA

79321390 - UNISTAC

Follow

Information

  • Trademark
  • 79321390
  • Serial Number
    79321390
  • Registration Number
    7184963
  • Filing Date
    August 06, 2021
    3 years ago
  • Registration Date
    October 10, 2023
    a year ago
  • Transaction Date
    January 30, 2024
    a year ago
  • Status Date
    October 10, 2023
    a year ago
  • Published for Opposition Date
    February 21, 2023
    2 years ago
  • Location Date
    October 10, 2023
    a year ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    DYER, ERIN ZASKODA
  • Attorney Docket Number
    39960-00070
    Attorney Name
    Connie L. Ellerbach
    Law Office Assigned Location Code
    L30
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
UNISTAC
Case File Statements
  • GS0051: Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the prevention of diabetes; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; cardiovascular treatment preparations; pharmaceutical preparations for the prevention of disorders of the nervous system; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the treatment of inflammatory diseases; antibacterial pharmaceuticals; pharmaceutical drugs being pharmaceutical preparations namely, for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; synthetic peptides for pharmaceutical purposes namely, for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; pharmaceutical compositions for the treatment of autoimmune diseases, cardiovascular diseases and disorders, central nervous system diseases, inflammatory diseases and disorders, metabolic diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders; clinical medical reagents; clinical diagnostic reagents for medicinal use; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for use in tissue transplantation; tissue-regenerative pharmaceutical preparations; pharmaceutical preparations for tumor treatment; stimulants for the central nervous system; pharmaceutical preparations for the treatment of central nervous system [CNS] diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for treating respiratory diseases
  • PM0001: UNI STAC; UNI STACK
  • GS0421: Research and development of vaccines and medicines; research and development of technology for biotechnology; development of biotechnology; research relating to biotechnology; laboratory research in the field of biology; biological research services; development of new technologies in the field of biologics; drug discovery services; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; research in the field of pharmacogenetics; development of pharmaceutical preparations and medicines; laboratory research in the field of pharmaceuticals; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs; pharmaceutical drug development services; pharmaceutical research and development; research relating to pharmaceuticals; scientific research in the field of pharmacy; medical laboratory services; research relating to new technologies for medical treatment; medical research laboratory services; scientific research for medical purposes in the area of cancerous diseases; research and development of new technologies for others in the field of amino acid for medical purpose; research and development of new technologies for others in the field of peptide for medical purposes; research and development of technology for medicinal chemical manufacturing; medicine research; scientific research relating to medical substances; medical research; scientific research relating to chemistry
Case File Event Statements
  • 1/30/2024 - a year ago
    36 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 1/10/2024 - a year ago
    35 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 1/10/2024 - a year ago
    34 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 1/10/2024 - a year ago
    33 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 10/10/2023 - a year ago
    32 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 10/10/2023 - a year ago
    31 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 8/31/2023 - a year ago
    30 - EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED Type: ETOP
  • 3/20/2023 - 2 years ago
    29 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 3/17/2023 - 2 years ago
    28 - EXTENSION OF TIME TO OPPOSE RECEIVED Type: ETOF
  • 3/1/2023 - 2 years ago
    27 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 3/1/2023 - 2 years ago
    26 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 2/21/2023 - 2 years ago
    25 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 2/21/2023 - 2 years ago
    24 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 2/20/2023 - 2 years ago
    23 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 2/1/2023 - 2 years ago
    22 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 2/1/2023 - 2 years ago
    21 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 2/1/2023 - 2 years ago
    20 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 1/18/2023 - 2 years ago
    19 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 12/15/2022 - 2 years ago
    18 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 12/14/2022 - 2 years ago
    17 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 12/14/2022 - 2 years ago
    16 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 10/26/2022 - 2 years ago
    15 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 10/26/2022 - 2 years ago
    14 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 10/26/2022 - 2 years ago
    13 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR
  • 10/26/2022 - 2 years ago
    12 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 10/26/2022 - 2 years ago
    11 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 10/26/2022 - 2 years ago
    10 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 7/5/2022 - 2 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 6/15/2022 - 2 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 6/15/2022 - 2 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 5/13/2022 - 3 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 5/12/2022 - 3 years ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 5/6/2022 - 3 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 10/9/2021 - 3 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 10/5/2021 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 9/30/2021 - 3 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR